Latest on Ultrasound Renal Denervation
Published: 22 June 2022
Part 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp
Part 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder
Part 4 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane
Part 4 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial
Part 6 | Session 1 RADIANCE II Pivotal Trial
Part 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
Part 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
Part 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Interventional radiologists
More from this programme
The Science of uRDN
The Evidence for uRDN
Results From the Latest Clinical Trials
Patient Perspective & Provider Referral Development
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
Prof Philipp Lurz is Deputy Head of the Department at Heart Center Leipzig, Germany, a position he has held since 2018. Previously, Prof Lurz was a Clinical Research Fellow at Great Ormond Street Hospital for Children NHS Foundation Trust. He completed his education at the University of Leipzig, and is a member of the German Society of Cardiology. Philipp is widely published in leading international peer-reviewed journals.
Head of the Preclinical Research
Dr Michael Joner MD completed his medical training at the University of Wuerzburg and spent 2004-2006 as a cardiovascular pathology fellow at the CVPath Institute.
After returning to Germany, since 2007 Dr Joner has been Head of the Preclinical Research at the German Heart Centre in Munich, where he also completed his interventional cardiology residency.
Associate Professor and Senior Physician
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.
Former Vice President, Research & Development, ReCor Medical
Mr Wu has over 20 years of experience in medical device product development. He has worked on devices in the fields of interventional cardiology, electrophysiology, pulmonology, and women’s health, and has taken a number of them from early concept phase through clinical or commercial launch.